Research programme: T-cell adoptive immunotherapy - Cellectis

Drug Profile

Research programme: T-cell adoptive immunotherapy - Cellectis

Alternative Names: UCART 38; UCART-22; UCART-CS1

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellectis
  • Developer Cellectis; Pfizer; Servier; University College London
  • Class CAR-T cell therapies
  • Mechanism of Action Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Multiple myeloma; Solid tumours

Most Recent Events

  • 16 Jan 2018 Adhoc task (BCMA-CART profiles) - removed immunomodulators and cell replacements, and added T-lymphocyte replacements
  • 10 Dec 2017 Pharmacodynamics data from a preclinical trial in Multiple myeloma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
  • 09 Dec 2017 Pharmacodynamics data from a preclinical trial in Acute lymphoblastic leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top